Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.11
Percentage change -3.43	%

Peers: SRPT FATE KURA ADVM RIGL XERS IMUX PRQR CLSD MTEM

| Held by: HRTS CANC IDNA GWX BBC

Index	-	P/E	-	EPS (ttm)	-	Insider Own	8.16%	Shs Outstand	154.73M	Perf Week	5.80%
Market Cap	479.66M	Forward P/E	-	EPS next Y	-0.03	Insider Trans	-3.20%	Shs Float	142.11M	Perf Month	-17.55%
Income	-	PEG	-	EPS next Q	-0.01	Inst Own	62.69%	Short Float	5.07%	Perf Quarter	-22.69%
Sales	-	P/S	-	EPS this Y	-53.57%	Inst Trans	7.25%	Short Ratio	6.86	Perf Half Y	-19.06%
Book/sh	0.47	P/B	6.61	EPS next Y	58.14%	ROA	-	Short Interest	7.20M	Perf Year	-22.31%
Cash/sh	0.52	P/C	5.96	EPS next 5Y	6.69%	ROE	-	52W Range	2.53 - 5.02	Perf YTD	-11.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	41.78%	ROI	-	52W High	-38.25%	Beta	0.94
Dividend TTM	-	Quick Ratio	6.10	Sales past 5Y	-25.00%	Gross Margin	-	52W Low	22.77%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	6.10	EPS Y/Y TTM	-21.83%	Oper. Margin	-	RSI (14)	46.50	Volatility	4.96% 6.64%
Employees	33	Debt/Eq	0.09	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.12	Target Price	7.34
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	-	Payout	-	Rel Volume	0.92	Prev Close	3.21
Sales Surprise	-	EPS Surprise	-11.11%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	1.05M	Price	3.10
SMA20	0.75%	SMA50	-8.48%	SMA200	-17.53%	Trades		Volume	963,883	Change	-3.43%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-06-24	Initiated	Jefferies	Buy	$7
Jun-13-24	Initiated	Robert W. Baird	Outperform	$8
Oct-13-23	Resumed	BTIG Research	Buy	$4
Aug-12-22	Initiated	Cantor Fitzgerald	Overweight	$4
May-05-21	Initiated	BTIG Research	Buy	$10
Apr-05-21	Initiated	Needham	Buy	$10

Jan-12-25 11:05AM	Mereo BioPharma Provides Update on Lead Clinical Programs (GlobeNewswire)
Jan-07-25 07:30AM	Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:50PM	Why Mereo BioPharma (MREO) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey) -5.63%
Dec-07-24 05:20AM	Mereo BioPharma initiated with a Buy at Jefferies (TipRanks)
Dec-06-24 01:18PM	Mereo BioPharma Stock Climbs Following Jefferies' Buy Rating, Upside Potential of 89% (GuruFocus.com) +8.65%
07:30AM	Loading…
Nov-14-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire) -5.68%
Nov-12-24 07:30AM	Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-16-24 09:06AM	Is Mereo BioPharma Group (MREO) the Hottest Penny Stock to Invest in According to Hedge Funds? (Insider Monkey)
Sep-18-24 08:21AM	Mereo BioPharma Group plc (MREO): A Bull Case Theory (Insider Monkey) +6.84%
Sep-12-24 05:35PM	Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference (GlobeNewswire) -5.79%
Aug-13-24 08:00AM	Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-15-24 11:42PM	Street calls of the week: Upgrade for Shopify; downgrades for AMD, Paramount (Investing.com)
Jun-14-24 07:50AM	Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market (GlobeNewswire) +6.52%
Jun-12-24 07:45AM	Ultragenyx, Mereo drug reduces fractures in bone disorder study (BioPharma Dive) +8.81%
Jun-11-24 05:47PM	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
07:30AM	Loading…
May-30-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire) +5.90%
May-15-24 04:01PM	Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +7.09%
Apr-12-24 09:35AM	MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-03-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-24 05:27PM	Mereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results (GuruFocus.com) +10.00%
04:01PM	Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 07:30AM	Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey)
Jan-08-24 07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Dec-19-23 11:21AM	Hedge Funds Say These Penny Stocks Are Poised to Explode (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks)
Oct-23-23 04:01PM	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update (GlobeNewswire) -7.89%
Oct-14-23 04:30PM	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-09-23 08:00AM	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-21-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference (GlobeNewswire) -5.67%
07:30AM	Loading…
Sep-07-23 07:30AM	Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update (GlobeNewswire)
Aug-10-23 11:04PM	BAKER BROS. ADVISORS LP Acquires Significant Stake in Mereo BioPharma Group PLC (GuruFocus.com) -6.30%
Aug-04-23 08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Jul-07-23 07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks) +7.32%
Jul-06-23 08:00AM	Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
May-31-23 07:00AM	Mereo BioPharma to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-23-23 01:43PM	Phase 2 Data from ASTRAEUS Trial of Mereo BioPharmas Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference (GlobeNewswire) -5.47%
May-08-23 12:46PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
May-05-23 04:06PM	Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market (GlobeNewswire)
Apr-21-23 12:00PM	What Makes MEREO BIOPHARMA (MREO) a Strong Momentum Stock: Buy Now? (Zacks) -5.72%
Apr-13-23 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference (GlobeNewswire)
Mar-28-23 04:30PM	Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights (GlobeNewswire)
Mar-21-23 06:30AM	Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease (GlobeNewswire) +16.89%
Feb-08-23 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference (GlobeNewswire)
Jan-10-23 05:35AM	Positive week for Mereo BioPharma Group plc (NASDAQ:MREO) hedge funds investors who lost 33% over the past year (Simply Wall St.) -7.12%
Nov-15-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +5.92%
Nov-08-22 07:00AM	Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-02-22 04:01PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire) -6.97% -8.76%
Oct-28-22 07:00AM	Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management (GlobeNewswire)
Oct-24-22 04:30PM	Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022 (GlobeNewswire)
Oct-21-22 07:00AM	Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting (GlobeNewswire)
Oct-18-22 11:58AM	Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan (Business Wire)
07:00AM	Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value (GlobeNewswire)
Oct-17-22 07:00AM	Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease (GlobeNewswire)
Oct-03-22 05:00PM	Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders (GlobeNewswire) +7.85%
09:00AM	Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five (Business Wire)
Sep-28-22 09:21AM	Chinese Billionaire Zhang Lei is Selling These 10 Stocks (Insider Monkey)
Sep-26-22 07:00AM	Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board (GlobeNewswire)
Sep-14-22 09:00AM	Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders (Business Wire)
Sep-12-22 08:00AM	Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors (GlobeNewswire)
Sep-09-22 08:22PM	Ultragenyx and Mereo BioPharma to Present Setrusumab Data Update at ASBMR (GlobeNewswire) +5.94%
Aug-31-22 07:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)
Aug-22-22 04:00AM	Mereo BioPharma Sends Letter to Rubric Capital Management (GlobeNewswire)
Jul-05-22 04:01PM	Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) -6.52%
Jun-21-22 08:30AM	CEOs of NIO, NEXCF, MREO, and AIMLF Advancing Next Wave of Multi-Billion Dollar Growth Opportunities in Web 3.0, Wearables, Pharma, and Electric Vehicles. (GlobeNewswire) +30.00%
Jun-20-22 10:36AM	Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout (Zacks)
Jun-17-22 05:30PM	Mereo BioPharm and Theseus Pharmaceuticals See Action From Activist Investors (Barrons.com) +62.50% +30.00%
03:53PM	AstraZeneca weighs bid for Mereo, Carnival Cruises partners with MGM, Devon Energy stock plunges (Yahoo Finance Video)
10:21AM	Why Mereo BioPharma Shares Are Jumping Today (Benzinga)
03:44AM	AstraZeneca weighing bid for Mereo BioPharma: report (MarketWatch)
Jun-02-22 08:00AM	Mereo BioPharma To Present Data Update for the Phase 1b/2 Study (ACTIVATE) of Etigilimab and Nivolumab at 2022 ASCO Annual Meeting; Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan (GlobeNewswire) -5.12%
May-26-22 05:05PM	Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +8.77%
04:30PM	Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency (GlobeNewswire)
May-17-22 08:00AM	Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors (GlobeNewswire)
May-09-22 07:45AM	Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease (Benzinga) -31.30%
07:00AM	Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from ASTRAEUS Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema (GlobeNewswire)
May-06-22 05:12PM	Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from ASTRAEUS Phase 2 Study of Alvelestat (GlobeNewswire)
05:12PM	Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from ASTRAEUS Phase 2 Study of Alvelestat (GlobeNewswire)
Apr-22-22 09:35AM	MEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Apr-06-22 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-31-22 04:01PM	Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights (GlobeNewswire) +7.69%
Mar-03-22 08:30AM	Mereo BioPharma to Hold Virtual R&D Day on Monday, March 14, 2022 (GlobeNewswire)
Mar-01-22 08:00AM	Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors (GlobeNewswire)
Feb-10-22 08:00AM	Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -6.67%
Jan-12-22 01:59PM	Do Hedge Funds Love Mereo BioPharma Group plc (MREO)? (Insider Monkey)
Dec-29-21 01:19AM	UAB and Mereo BioPharma Group post positive results from Covid-19 clinical trial (American City Business Journals)
Dec-22-21 07:00AM	UAB and Mereo Announce Positive Top-line Results from COSTA a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease (GlobeNewswire)
Dec-17-21 12:38AM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com) +7.55%
Dec-15-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com)
Dec-13-21 07:00AM	Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereos Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting (GlobeNewswire)
Dec-10-21 09:38PM	Rubric Capital Management LP Buys Ferroglobe PLC, AdaptHealth Corp, CF Industries Holdings Inc, ... (GuruFocus.com)
Nov-30-21 07:00AM	Mereo BioPharma Reports Interim Data from ACTIVATE Phase 1b/2 Open Label Study of etigilimab Anti-TIGIT Antibody in combination with Nivolumab in Solid Tumors (GlobeNewswire)
Nov-09-21 08:00AM	Mereo BioPharma to Present at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-21 09:00AM	Data from Investigator-sponsored Trial of Mereo BioPharmas alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-31-21 10:30AM	2 Growth Stocks That Could Deliver 1,000% Returns (Motley Fool)
Oct-26-21 10:26AM	Hedge Funds Are Crazy About Mereo BioPharma Group plc (MREO) (Insider Monkey)
08:00AM	Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in the Treatment of alpha-1 antitrypsin deficiency (GlobeNewswire)
Oct-13-21 08:00AM	Mereo BioPharma, the Osteogenesis Imperfecta Federation Europe (OIFE) and the Osteogenesis Imperfecta Foundation (OIF) announces completion of the IMPACT Survey enrollment (GlobeNewswire)
Oct-01-21 04:31PM	Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting (GlobeNewswire) +7.02% -10.04%
Sep-20-21 08:00AM	Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors (GlobeNewswire) -5.30%

Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Scots-Knight Denise	Chief Executive Officer	Sep 13 '24	Sale	4.22	60,046	253,454	808,921	Sep 16 08:50 PM
Scots-Knight Denise	Chief Executive Officer	Sep 12 '24	Sale	4.47	28,611	127,968	868,967	Sep 16 08:50 PM
Lewicki John A.	Chief Scientific Officer	Sep 13 '24	Sale	4.22	10,937	46,165	78,630	Sep 16 08:49 PM
Lewicki John A.	Chief Scientific Officer	Sep 12 '24	Sale	4.47	5,212	23,312	89,567	Sep 16 08:49 PM
Sermon Charles	General Counsel	Sep 13 '24	Sale	4.22	20,946	88,413	219,061	Sep 16 08:48 PM
Sermon Charles	General Counsel	Sep 12 '24	Sale	4.47	9,980	44,638	240,007	Sep 16 08:48 PM
Fox Christine Ann	Chief Financial Officer	Sep 13 '24	Sale	4.22	19,158	80,866	89,285	Sep 16 08:47 PM
Fox Christine Ann	Chief Financial Officer	Sep 12 '24	Sale	4.47	9,128	40,827	108,443	Sep 16 08:47 PM
Hughes-Wilson Alexandra	See Remarks	Sep 13 '24	Sale	4.22	100,312	423,417	50,475	Sep 16 08:46 PM
Hughes-Wilson Alexandra	See Remarks	Sep 12 '24	Sale	4.47	47,798	213,786	150,787	Sep 16 08:46 PM
Sermon Charles	General Counsel	Sep 11 '24	Option Exercise	0.00	65,600	0	249,987	Sep 13 04:57 PM
Fox Christine Ann	Chief Financial Officer	Sep 11 '24	Option Exercise	0.00	60,000	0	117,571	Sep 13 04:50 PM
Lewicki John A.	Chief Scientific Officer	Sep 11 '24	Option Exercise	0.00	46,000	0	94,779	Sep 13 04:49 PM
Scots-Knight Denise	Chief Executive Officer	Sep 11 '24	Option Exercise	0.00	188,060	0	897,578	Sep 13 04:49 PM
Hughes-Wilson Alexandra	See Remarks	Sep 11 '24	Option Exercise	0.99	208,333	206,416	242,881	Sep 13 04:47 PM
Alexandra Hughes-Wilson	Officer	Sep 12 '24	Proposed Sale	4.66	148,110	690,193		Sep 12 04:05 PM
Scots-Knight Denise	Officer	Sep 12 '24	Proposed Sale	4.66	88,657	413,142		Sep 12 04:05 PM
Sermon Charles	Officer	Sep 12 '24	Proposed Sale	4.66	30,926	144,115		Sep 12 04:05 PM
Lewicki John A.	Officer	Sep 12 '24	Proposed Sale	4.66	16,149	75,254		Sep 12 04:05 PM
Fox Christine Ann	Officer	Sep 12 '24	Proposed Sale	4.66	28,286	131,813		Sep 12 04:05 PM
PAKIANATHAN DEEPIKA	Director	Aug 22 '24	Option Exercise	1.44	105,244	151,116	105,244	Aug 23 06:13 PM
PAKIANATHAN DEEPIKA	Director	Aug 22 '24	Sale	4.43	105,244	466,210	0	Aug 23 06:13 PM
Deepika Pakianathan	Director	Aug 22 '24	Proposed Sale	4.43	105,244	466,210		Aug 22 06:35 PM
Sermon Charles	General Counsel	Jun 26 '24	Sale	3.39	32,187	109,217	184,387	Jun 27 04:15 PM
Sermon Charles	General Counsel	Jun 25 '24	Sale	3.69	14,202	52,461	216,574	Jun 27 04:15 PM
Lewicki John A.	Chief Scientific Officer	Jun 26 '24	Sale	3.39	16,808	57,033	48,779	Jun 27 04:15 PM
Lewicki John A.	Chief Scientific Officer	Jun 25 '24	Sale	3.69	7,416	27,394	65,587	Jun 27 04:15 PM
Fox Christine Ann	Chief Financial Officer	Jun 26 '24	Sale	3.39	29,439	99,892	57,571	Jun 27 04:15 PM
Fox Christine Ann	Chief Financial Officer	Jun 25 '24	Sale	3.69	12,990	47,984	87,010	Jun 27 04:15 PM
Scots-Knight Denise	Chief Executive Officer	Jun 26 '24	Sale	3.39	92,273	313,101	709,518	Jun 27 04:15 PM
Scots-Knight Denise	Chief Executive Officer	Jun 25 '24	Sale	3.69	40,712	150,386	801,791	Jun 27 04:15 PM
Hughes-Wilson Alexandra	See Remarks	Jun 26 '24	Sale	3.39	22,968	77,935	34,548	Jun 27 04:15 PM
Hughes-Wilson Alexandra	See Remarks	Jun 25 '24	Sale	3.69	10,134	37,434	57,516	Jun 27 04:15 PM
Lewicki John A.	Chief Scientific Officer	Jun 21 '24	Option Exercise	0.00	69,000	0	73,003	Jun 25 06:21 PM
Scots-Knight Denise	Chief Executive Officer	Jun 21 '24	Option Exercise	0.00	282,090	0	842,503	Jun 25 06:15 PM
Sermon Charles	General Counsel	Jun 21 '24	Option Exercise	0.00	98,400	0	230,776	Jun 25 06:14 PM
Fox Christine Ann	Chief Financial Officer	Jun 21 '24	Option Exercise	0.00	90,000	0	100,000	Jun 25 06:13 PM
Hughes-Wilson Alexandra	See Remarks	Jun 21 '24	Option Exercise	0.00	60,000	0	67,650	Jun 25 06:13 PM
Hughes-Wilson Alexandra	See Remarks	May 22 '24	Option Exercise	1.23	168,333	206,416	100,983	May 23 09:54 PM
Hughes-Wilson Alexandra	See Remarks	May 22 '24	Sale	2.97	100,432	297,788	32,568	May 23 09:54 PM

Open in Screener

KPTI

Karyopharm Therapeutics Inc

Feb 06 • 04:00PM ET

0.6570

Dollar change -0.0150
Percentage change -2.23	%

Healthcare • Biotechnology • USA • NASD

KPTI Karyopharm Therapeutics Inc daily Stock Chart

Peers: BMY MRK GILD JNJ VRTX AMGN REGN PFE BIIB LLY

| Held by: VTI VXF FESM IWC CNCR CHNA BTEC

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	7.58%	Shs Outstand	125.30M	Perf Week	-1.07%
Market Cap	82.91M	Forward P/E	-	EPS next Y	-0.72	Insider Trans	-0.44%	Shs Float	116.62M	Perf Month	-20.75%
Income	-87.48M	PEG	-	EPS next Q	-0.26	Inst Own	47.20%	Short Float	16.98%	Perf Quarter	-29.58%
Sales	148.44M	P/S	0.56	EPS this Y	45.03%	Inst Trans	6.24%	Short Ratio	21.88	Perf Half Y	-21.79%
Book/sh	-1.27	P/B	-	EPS next Y	-4.57%	ROA	-38.08%	Short Interest	19.80M	Perf Year	-51.33%
Cash/sh	1.06	P/C	0.62	EPS next 5Y	24.25%	ROE	-	52W Range	0.58 - 1.95	Perf YTD	-2.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	16.79%	ROI	-282.69%	52W High	-66.31%	Beta	0.08
Dividend TTM	-	Quick Ratio	2.93	Sales past 5Y	56.57%	Gross Margin	95.62%	52W Low	13.10%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	3.00	EPS Y/Y TTM	43.16%	Oper. Margin	-84.86%	RSI (14)	46.49	Volatility	8.27% 8.92%
Employees	325	Debt/Eq	-	Sales Y/Y TTM	1.77%	Profit Margin	-58.93%	Recom	1.57	Target Price	4.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	14.92%	Payout	-	Rel Volume	0.57	Prev Close	0.67
Sales Surprise	2.27%	EPS Surprise	1.10%	Sales Q/Q	7.70%	Earnings	Nov 05 BMO	Avg Volume	904.73K	Price	0.66
SMA20	-1.66%	SMA50	-7.81%	SMA200	-23.21%	Trades		Volume	517,875	Change	-2.23%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-19-23	Initiated	Piper Sandler	Overweight	$8
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$7 → $10
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral	$8
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight	$27 → $10
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$6
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$17 → $8
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-02-20	Initiated	Morgan Stanley	Overweight	$34
Mar-04-20	Initiated	Barclays	Overweight	$30
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight	$8 → $16
Jul-05-19	Reiterated	Robert W. Baird	Outperform	$15 → $25
Jul-05-19	Reiterated	H.C. Wainwright	Buy	$29 → $32
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral	$21 → $7
Feb-28-19	Reiterated	BofA/Merrill	Underperform	$15 → $5
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform	$15 → $5
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy	$23
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform	$19
May-24-18	Downgrade	Wedbush	Outperform → Neutral	$20 → $19

Show Previous Ratings

Feb-03-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-13-25 08:30AM	Karyopharm Announces Preliminary Unaudited 2024 Revenue and 2025 Objectives (PR Newswire) -6.37%
Jan-07-25 09:28AM	Why Karyopharm Therapeutics (KPTI) Is Among the Best Penny Stocks to Invest In According to Media? (Insider Monkey) -7.21%
Jan-02-25 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +20.01%
07:00AM	Karyopharm Announces the Appointment of Lori Macomber as Chief Financial Officer (PR Newswire)
08:00AM	Loading…
Dec-09-24 08:00AM	Karyopharm Announces the Appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications (PR Newswire)
Dec-03-24 07:00AM	Karyopharm Therapeutics Provides Endometrial Cancer Program Update (PR Newswire)
Dec-02-24 07:00AM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-25-24 07:00AM	Karyopharm to Participate at the Piper Sandler 36th Annual Healthcare Conference (PR Newswire)
Nov-20-24 04:05PM	Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer (PR Newswire)
Nov-18-24 07:00AM	Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition (PR Newswire)
Nov-06-24 02:08AM	Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com)
Nov-05-24 07:30PM	Antengene to Present Results from Two Late-Stage Studies of Selinexor Signaling Potential Clinical Breakthrough at ASH 2024 (PR Newswire) -9.36%
12:45PM	Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript (Motley Fool)
08:40AM	Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:37AM	Loading…
07:37AM	Karyopharm Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress (PR Newswire)
Nov-04-24 07:14AM	Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Nov-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.75%
Oct-31-24 10:02AM	Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks) +17.81%
08:00AM	Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024 (PR Newswire)
07:30AM	Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis (PR Newswire)
Oct-30-24 04:30PM	Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 (PR Newswire)
Oct-25-24 01:01PM	Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares (GuruFocus.com)
Oct-17-24 10:35PM	Antengene Announces XPOVIO (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country (PR Newswire)
Oct-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.75% +16.70%
Sep-23-24 05:00AM	Antengene Announces XPOVIO (selinexor) Approved for Commercialization in Thailand (PR Newswire) -5.42%
Sep-05-24 09:35AM	Down -12.14% in 4 Weeks, Here's Why Karyopharm Therapeutics (KPTI) Looks Ripe for a Turnaround (Zacks) +11.93%
Sep-03-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -5.29%
07:00AM	Karyopharm to Participate at Upcoming Investor Conferences (PR Newswire)
05:52AM	Loading…
Sep-02-24 05:52AM	Pipeline Moves: Investigator-led oncology cell therapy trial terminated (Clinical Trials Arena)
Aug-07-24 02:56AM	Q2 2024 Karyopharm Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-06-24 10:30PM	Karyopharm Therapeutics (KPTI) Q2 2024 Earnings Call Transcript (Motley Fool)
09:25AM	Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:21AM	Karyopharm Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress (PR Newswire)
Aug-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.58%
Jul-31-24 04:05PM	Karyopharm to Report Second Quarter 2024 Financial Results on August 6, 2024 (PR Newswire) -6.72%
Jul-24-24 11:24PM	Karyopharm Therapeutics Inc. (KPTI): Is This One-Dollar Stock a Strong Buy Right Now? (Insider Monkey)
Jul-15-24 10:56AM	Karyopharm Therapeutics Inc. (KPTI): Is This Penny Stock A Good Buy Right Now? (Insider Monkey)
Jul-05-24 09:10AM	XPOVIO (selinexor) Approved for New Indication in DLBCL in China, Bringing a New Treatment Option to Patients in the Country (PR Newswire)
Jul-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.01%
Jun-26-24 04:42AM	Antengene Announces XPOVIO (selinexor) National Health Insurance Service Approval for Reimbursement in South Korea (PR Newswire) -8.71%
Jun-03-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -6.14%
Jun-01-24 01:45PM	Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates (PR Newswire)
May-29-24 04:05PM	Karyopharm to Participate at the Jefferies Global Healthcare Conference (PR Newswire)
May-23-24 06:45AM	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom (InvestorPlace)
May-09-24 11:10AM	Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:02AM	Karyopharm Therapeutics Inc (KPTI) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-08-24 10:36PM	Q1 2024 Karyopharm Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -7.27%
04:45PM	Karyopharm Therapeutics (KPTI) Q1 2024 Earnings Call Transcript (Motley Fool)
04:05PM	Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare Conference (PR Newswire)
12:54PM	KPTI Stock Earnings: Karyopharm Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:12AM	Karyopharm Therapeutics Reports Q1 2024 Financial Results: A Detailed Review (GuruFocus.com)
07:41AM	Karyopharm Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress (PR Newswire)
07:30AM	Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029 (PR Newswire)
May-02-24 04:30PM	Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024 (PR Newswire)
May-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-24-24 04:01PM	Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting (PR Newswire)
Apr-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -11.71%
Mar-06-24 04:05PM	Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences (PR Newswire) +6.83% +15.04%
Mar-04-24 11:53PM	Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ... (GuruFocus.com) +10.55%
Mar-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
09:21AM	Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 10:03PM	Q4 2023 Karyopharm Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -12.78%
06:15PM	Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript (Motley Fool)
08:40AM	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:50AM	Karyopharm Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress (PR Newswire)
Feb-25-24 01:37PM	7 Biotech Penny Stocks on the Verge of Clinical Trial Victory (InvestorPlace)
Feb-22-24 07:00AM	Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024 (PR Newswire) -6.61%
Feb-14-24 10:00AM	Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know (Zacks) +5.84%
Feb-01-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +19.96% +15.52%
Jan-08-24 08:30AM	Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives (PR Newswire) +11.90%
Jan-03-24 07:00AM	Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) -7.56%
Jan-02-24 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-13-23 08:47PM	Antengene Announces Inclusion of XPOVIO (selinexor) in 2023 China's National Reimbursement Drug List (PR Newswire) +8.25%
Dec-10-23 08:15PM	Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Nave Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1) (PR Newswire)
Dec-06-23 04:00AM	Antengene Announces XPOVIO Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma (PR Newswire)
Dec-01-23 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +10.66%
Nov-08-23 04:05PM	Karyopharm to Participate at Upcoming Investor Conferences (PR Newswire) -6.14% -7.56%
Nov-06-23 07:00AM	Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study (PR Newswire)
Nov-03-23 12:46PM	Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2023 Earnings Call Transcript (Insider Monkey) +16.91%
Nov-02-23 03:30PM	Karyopharm Therapeutics (KPTI) Q3 2023 Earnings Call Transcript (Motley Fool)
09:33AM	Karyopharm Therapeutics Inc (KPTI) Reports Q3 2023 Earnings, Total Revenue of $36.0 Million (GuruFocus.com)
09:20AM	Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH) (PR Newswire)
07:47AM	Karyopharm Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (PR Newswire)
Oct-30-23 08:00AM	Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma (PR Newswire)
Oct-26-23 07:00AM	Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023 (PR Newswire)
Oct-02-23 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) -8.96% +5.33%
Sep-26-23 07:00AM	Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings (PR Newswire) +7.08%
Sep-05-23 04:05PM	Karyopharm to Participate at Upcoming Investor Conferences (PR Newswire) -6.62% -7.87%
Sep-01-23 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.25%
08:00AM	Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors (PR Newswire)
Aug-17-23 08:44AM	11 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Aug-03-23 02:18PM	Dozens more biotech jobs axed as two firms make cuts (American City Business Journals)
Aug-02-23 02:00PM	Karyopharm Therapeutics (KPTI) Q2 2023 Earnings Call Transcript (Motley Fool)
08:45AM	Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Tops Revenue Estimates (Zacks)

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A, Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Paulson Richard A.	President and CEO	Feb 04 '25	Sale	0.65	4,099	2,664	1,120,158	Feb 05 04:16 PM
Paulson Richard A.	President and CEO	Jan 06 '25	Sale	0.78	4,055	3,175	1,124,257	Jan 07 04:03 PM
Paulson Richard A.	President and CEO	Dec 04 '24	Sale	0.81	3,620	2,932	1,128,312	Dec 05 04:15 PM
Paulson Richard A.	President and CEO	Nov 05 '24	Sale	0.91	3,675	3,346	1,131,932	Nov 06 04:06 PM
Paulson Richard A.	President and CEO	Oct 04 '24	Sale	0.88	3,607	3,172	1,135,607	Oct 07 04:44 PM
Mano Michael	SVP, General Counsel&Secretary	Sep 04 '24	Sale	0.72	3,971	2,866	273,881	Sep 05 04:28 PM
Paulson Richard A.	President and CEO	Sep 04 '24	Sale	0.72	3,667	2,647	1,139,214	Sep 05 04:26 PM
Mason Michael	EVP, CFO & Treasurer	Sep 04 '24	Sale	0.72	7,050	5,089	391,054	Sep 05 04:24 PM
Cheng Sohanya Roshan	EVP & Chief Commercial Officer	Sep 04 '24	Sale	0.72	5,356	3,866	404,051	Sep 05 04:13 PM
Paulson Richard A.	President and CEO	Aug 06 '24	Sale	0.93	3,608	3,355	1,142,881	Aug 08 04:31 PM
Poulton Stuart	EVP, Chief Development Officer	Jul 30 '24	Sale	1.06	2,883	3,056	326,628	Jul 31 04:14 PM
Paulson Richard A.	President and CEO	Jul 05 '24	Sale	0.85	3,616	3,077	1,146,489	Jul 09 04:15 PM
PAKIANATHAN DEEPIKA	Director	Jun 05 '24	Sale	0.96	468,044	448,480	3,385	Jun 07 07:18 PM
PAKIANATHAN DEEPIKA	Director	Jun 07 '24	Sale	0.95	231,548	220,133	0	Jun 07 07:18 PM
PAKIANATHAN DEEPIKA	Director	Jun 06 '24	Sale	0.98	118,452	116,415	2,240	Jun 07 07:18 PM
Mason Michael	EVP, CFO & Treasurer	Jun 04 '24	Sale	0.99	652	645	398,104	Jun 06 04:03 PM
Paulson Richard A.	President and CEO	Jun 04 '24	Sale	0.99	3,592	3,556	1,150,105	Jun 06 04:02 PM
PAKIANATHAN DEEPIKA	Director	Jun 03 '24	Sale	1.00	360,744	360,997	11,209	Jun 04 06:51 PM
PAKIANATHAN DEEPIKA	Director	Jun 04 '24	Sale	0.95	341,040	324,704	7,911	Jun 04 06:51 PM
PAKIANATHAN DEEPIKA	Director	May 31 '24	Sale	0.95	204,394	194,992	14,697	Jun 04 06:51 PM
Paulson Richard A.	President and CEO	May 06 '24	Sale	1.13	3,576	4,041	1,153,697	May 07 04:56 PM
Rangwala Reshma	EVP & Chief Medical Officer	Apr 22 '24	Sale	1.17	6,789	7,943	342,931	Apr 23 04:02 PM
Paulson Richard A.	President and CEO	Apr 04 '24	Sale	1.29	3,563	4,596	1,157,273	Apr 05 05:20 PM
Paulson Richard A.	President and CEO	Mar 05 '24	Sale	1.30	3,573	4,645	1,160,836	Mar 06 04:14 PM
Rangwala Reshma	EVP & Chief Medical Officer	Feb 29 '24	Sale	1.17	15,667	18,330	355,689	Mar 04 07:41 PM
Rangwala Reshma	EVP & Chief Medical Officer	Mar 01 '24	Sale	1.20	5,969	7,163	349,720	Mar 04 07:41 PM
Poulton Stuart	EVP, Chief Development Officer	Feb 29 '24	Sale	1.17	16,311	19,084	335,666	Mar 04 07:40 PM
Poulton Stuart	EVP, Chief Development Officer	Mar 01 '24	Sale	1.20	6,155	7,386	329,511	Mar 04 07:40 PM
Mason Michael	EVP, CFO & Treasurer	Feb 29 '24	Sale	1.17	27,687	32,394	404,918	Mar 04 07:39 PM
Mason Michael	EVP, CFO & Treasurer	Mar 01 '24	Sale	1.20	6,162	7,394	398,756	Mar 04 07:39 PM
Mano Michael	SVP, General Counsel&Secretary	Feb 29 '24	Sale	1.17	16,973	19,858	281,428	Mar 04 07:38 PM
Mano Michael	SVP, General Counsel&Secretary	Mar 01 '24	Sale	1.20	3,576	4,291	277,852	Mar 04 07:38 PM
Cheng Sohanya Roshan	EVP & Chief Commercial Officer	Feb 29 '24	Sale	1.17	21,840	25,553	398,618	Mar 04 07:37 PM
Cheng Sohanya Roshan	EVP & Chief Commercial Officer	Mar 01 '24	Sale	1.20	5,109	6,131	393,509	Mar 04 07:37 PM
Paulson Richard A.	President and CEO	Feb 29 '24	Sale	1.17	80,470	94,150	1,183,783	Mar 04 07:36 PM
Paulson Richard A.	President and CEO	Mar 01 '24	Sale	1.20	19,374	23,249	1,164,409	Mar 04 07:36 PM
Mason Michael	EVP, CFO & Treasurer	Feb 27 '24	Sale	1.32	2,545	3,369	244,400	Feb 29 05:35 PM
Poulton Stuart	EVP, Chief Development Officer	Feb 15 '24	Sale	1.33	5,847	7,783	163,772	Feb 20 04:59 PM

MREO

Mereo Biopharma Group Plc ADR

KPTI

Karyopharm Therapeutics Inc

Upgrade your FINVIZ experience